Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  European Journal of Cancer

• Publication date

  2005-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EJCA.2005.04.029PMID 16051481
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy

  2012cited by this paper
• Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

  2004cited by this paper
• Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.

  2002cited by this paper
• EGFR and cancer prognosis.

  2001cited by this paper
• Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

  2001cited by this paper
• Epidermal growth factor receptor biology (IMC-C225)

  2001cited by this paper
• Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

  2001cited by this paper
• Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c- jun N-terminal kinase activity

  2000cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

  2000cited by this paper
• Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.

  2000cited by this paper
• The EGF receptor family as targets for cancer therapy

  2000cited by this paper
• Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.

  1999cited by this paper
• Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

  1999cited by this paper
• Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

  1998cited by this paper
• Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.

  1997cited by this paper
• Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.

  1997cited by this paper
• Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

  1997cited by this paper
• Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.

  1997cited by this paper
• Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704.

  1996cited by this paper
• In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals

  1995cited by this paper
• Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852.

  1994cited by this paper
• Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.

  1993cited by this paper
• Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients.

  1992cited by this paper
• Epidermal growth factor: the receptor and its function.

  1989cited by this paper
• The epidermal growth factor receptor as a multifunctional allosteric protein.

  1988cited by this paper

• Thermosensitive chitosan hydrogel loaded cetuximab: a novel approach for parenteral controlled delivery

  2025cites this paper
• Insulin-like Growth Factor 2-Tagged Aptamer Chimeras (ITACs) Modular Assembly for Targeted and Efficient Degradation of Two Membrane Proteins.

  2023cites this paper
• Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas

  2021cites this paper
• Development and validation of a rapid RP-HPLC method for simultaneous quantification of paclitaxel and cetuximab in immunoliposomes.

  2021cites this paper
• A phospho-proteomic study of cetuximab resistance in KRAS/NRAS/BRAFV600 wild-type colorectal cancer

  2021cites this paper
• Cetuximab in locally advanced head and neck squamous cell carcinoma: biological mechanisms involved in efficacy, toxicity and resistance.

  2021cites this paper
• Comparison Between Biweekly and Weekly Cetuximab in Patients With Metastatic Colorectal Cancer: A Meta-analysis

  2020cites this paper
• A Critical Review of Properties and Analytical/Bioanalytical Methods for Characterization of Cetuximab

  2020cites this paper
• Lipid Vesicles Loaded with an HIV-1 Fusion Inhibitor Peptide as a Potential Microbicide

  2020cites this paper
• Automated flow fluorescent noncompetitive immunoassay for measurement of human plasma levels of monoclonal antibodies used for immunotherapy of cancers with KinExA™ 3200 biosensor.

  2019cites this paper
• Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study

  2018cites this paper
• Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.

  2016cites this paper
• Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics

  2016cites this paper
• Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes.

  2016cites this paper
• Platinum‐based chemotherapy plus cetuximab first‐line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open‐label, single‐arm, multicenter trial

  2015cites this paper
• Impact of CAPOX or FOLFOX4 on Spleen size, Platelet Count and Liver Function when Partnered Cetuximab as First-line Treatment for KRAS Wild-type Metastatic Colorectal Cancer

  2015cites this paper
• Pharmakokinetik und metabolische Aktivierung von Capecitabin in der Kombinationstherapie mit Oxaliplatin und dem monoklonalen Antikörper Cetuximab

  2014cites this paper
• Cetuximab increases concentrations of irinotecan and of its active metabolite SN‐38 in plasma and tumour of human colorectal carcinoma‐bearing mice

  2014cites this paper
• Molecular confocal laser endomicroscopy: a novel technique for in vivo cellular characterization of gastrointestinal lesions.

  2014cites this paper
• Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers

  2014cites this paper
• ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools.

  2013cites this paper
• Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer

  2013cites this paper
• Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer

  2013cites this paper
• Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer

  2013cites this paper
• Principles of Cancer Biotherapy 5

  2013influential citation
• Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.

  2013cites this paper
• Scientific Perspectives on Therapeutic Protein Drug–Drug Interaction Assessments

  2013cites this paper
• Monoclonal Antibodies in Cancer

  2013cites this paper
• Logistic Considerations in Study Design for Biologic Drug–Drug Interaction Assessments

  2013cites this paper
• Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters

  2012cites this paper
• Anti‐EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab

  2012cites this paper
• Evaluation of interstitial protein delivery in multicellular layers model

  2012cites this paper
• Cetuximab in metastatic colorectal cancer

  2012cites this paper
• A comparison of in vitro methods for determining the membrane receptor expression in cell lines.

  2012cites this paper
• A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer

  2012cites this paper
• Cetuximab

  2012cites this paper
• The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis.

  2011cites this paper
• Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors

  2011cites this paper
• Cost savings from dose rounding of biologic anticancer agents in adults

  2011cites this paper
• Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors

  2011cites this paper
• Therapeutic monoclonal antibody concentration monitoring: free or total?

  2010cites this paper
• Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

  2010cites this paper
• MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer

  2010cites this paper
• Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer.

  2010cites this paper
• Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

  2010cites this paper
• Drug interactions among the epidermal growth factor receptor inhibitors, other biologics and cytotoxic agents.

  2010cites this paper
• Cetuximab

  2010cites this paper
• EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?

  2010cites this paper
• Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

  2010cites this paper
• Population pharmacokinetics of therapeutic monoclonal antibodies: Examples and estimation method performance differences

  2010cites this paper
• An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics

  2010cites this paper
• Therapeutic Protein–Drug Interactions and Implications for Drug Development

  2010cites this paper
• Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab

  2010cites this paper
• Monoclonal antibody therapy

  2009cites this paper
• A new approach for pharmacokinetics of single-dose cetuximab in rhesus monkeys by surface plasmon resonance biosensor.

  2009cites this paper
• Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges

  2009cites this paper
• A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors

  2009cites this paper
• Pharmacocinétique des anticorps monoclonaux

  2009cites this paper
• Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.

  2009cites this paper
• Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies

  2009cites this paper
• An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab

  2009cites this paper
• Pharmacologic intervention for cancer-related dyspnea.

  2008cites this paper
• Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis.

  2008cites this paper
• Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and Neck

  2008cites this paper
• Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?

  2008cites this paper
• Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.

  2008cites this paper
• Développement de techniques analytiques pour l'évaluation des protéines thérapeutiques et des biomarqueurs par spectrométrie de masse

  2008cites this paper
• Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials.

  2008cites this paper
• Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.

  2008cites this paper
• Clinical Use of Anti‐Epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer

  2008cites this paper
• Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered

  2007cites this paper
• Pharmacology of Epidermal Growth Factor Inhibitors

  2007cites this paper
• Pharmacokinetic Drug‐Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check

  2007cites this paper
• Pharmacology of epidermal growth factor inhibitors.

  2007cites this paper
• Feasibility of Using Cetuximab and Bevacizumab in a Patient with Colorectal Cancer and Terminal Renal Failure

  2007cites this paper
• Cetuximab in the treatment of metastatic colorectal cancer

  2007cites this paper
• In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab.

  2006cites this paper
• Targeting the epidermal growth factor receptor (EGFR)--a new therapeutic option in oncology?

  2006cites this paper
• Cetuximab in the treatment of head and neck cancer

  2006cites this paper